Emergent Biosolutions Inc. (NYSE:EBS) Shares Bought by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers increased its holdings in Emergent Biosolutions Inc. by 28.5%, owning a total of 356,281 shares valued at approximately $1.73 million as of the latest SEC filing.
• Many institutional investors are active in Emergent Biosolutions, with entities like Millennium Management LLC and Invesco Ltd. significantly raising their stakes, indicating strong institutional interest in the biopharmaceutical firm.
• Emergent Biosolutions reported $0.16 earnings per share for the last quarter, surpassing expectations, despite revenue falling short of estimates at $140.90 million.

Cetera Investment Advisers lifted its position in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 28.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 356,281 shares of the biopharmaceutical company's stock after buying an additional 79,034 shares during the period. Cetera Investment Advisers owned approximately 0.66% of Emergent Biosolutions worth $1,732,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Bank of America Corp DE grew its position in Emergent Biosolutions by 4.4% during the 4th quarter. Bank of America Corp DE now owns 332,099 shares of the biopharmaceutical company's stock worth $3,175,000 after purchasing an additional 14,054 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Emergent Biosolutions by 70.9% in the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after acquiring an additional 638,995 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Emergent Biosolutions by 22.4% in the first quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company's stock worth $1,823,000 after acquiring an additional 68,748 shares during the period. Harbor Capital Advisors Inc. acquired a new position in shares of Emergent Biosolutions in the first quarter worth about $179,000. Finally, Barclays PLC raised its position in Emergent Biosolutions by 140.5% during the fourth quarter. Barclays PLC now owns 94,523 shares of the biopharmaceutical company's stock worth $904,000 after acquiring an additional 55,215 shares during the period. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Trading Down 0.1%

Shares of EBS traded down $0.01 during mid-day trading on Wednesday, reaching $8.90. The stock had a trading volume of 401,060 shares, compared to its average volume of 1,254,265. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.28. The business's fifty day moving average is $6.81 and its 200 day moving average is $6.61. The firm has a market cap of $474.65 million, a price-to-earnings ratio of 3.64 and a beta of 1.97.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. The business had revenue of $140.90 million during the quarter, compared to analyst estimates of $148.55 million. On average, sell-side analysts predict that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research report on Saturday.

Insider Activity at Emergent Biosolutions

In related news, Director Keith Katkin sold 7,844 shares of the company's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the sale, the director owned 86,431 shares in the company, valued at $544,515.30. This represents a 8.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.20% of the stock is owned by insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.